Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Public ClinicalTrials.gov record NCT02547922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).
Study identification
- NCT ID
- NCT02547922
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 147 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 4, 2015 (Actual)
- Primary completion
- Nov 26, 2019 (Actual)
- Completion
- Jan 18, 2021 (Actual)
- Last update posted
- Nov 24, 2021
2015 – 2021
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Glendale | Arizona | 85306 | — |
| Research Site | Phoenix | Arizona | 85032 | — |
| Research Site | La Jolla | California | 92037-0706 | — |
| Research Site | Los Angeles | California | 90095-1670 | — |
| Research Site | Thousand Oaks | California | 91360 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | DeBary | Florida | 32713 | — |
| Research Site | Boston | Massachusetts | 02118 | — |
| Research Site | Newark | New Jersey | 07103-2499 | — |
| Research Site | Great Neck | New York | 11021 | — |
| Research Site | New Hyde Park | New York | 11042 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | The Bronx | New York | 10457 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Memphis | Tennessee | 38119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02547922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2021 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02547922 live on ClinicalTrials.gov.